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Backgroundandpurpose: Stent implantation is an important treatment option for pulmonary artery steno-
sis (PS), even if complicated by univentricular physiology (UVP). However, there is paucity of evidence
concerning not only its hemodynamic and morphologic indications but also on markers for its opti-
mal target attainment in UVP. The purpose of this study was to evaluate the acute outcome and factors
associated with efﬁcacy of stenting for PS complicating UVP.
Methods and subjects: A subanalysis was performed using the data of the Japanese Society of Pediatric
Interventional Cardiology (JPIC) stent survey. We analyzed the morphologic and hemodynamic data of
11 patients with UVPwho underwent stenting for PS.We deﬁned “a 50% increase in theminimum lumen
diameter (MLD)” as “morphologically effective,” and “an achievement of 0mmHg pressure gradient” as
“hemodynamically effective.” We analyzed the success rate for each criterion and determined factors
which may have contributed to hemodynamic effectiveness.
Results: Stenting wasmorphologically effective in all patients, while it was hemodynamically effective in
6/11 (55%). The percent diameter stenosis after stentingwas signiﬁcantly lower in the “hemodynamically
effective” group (2.5±5.5% vs 19.6±13.1%, p=0.017). The cutoff value of percent diameter stenosis after
stenting to “hemodynamically effective” was 14.6%; the sensitivity was 80% and the speciﬁcity was 100%
(area under the curve 0.825, p=0.021).
Conclusions: The percent diameter stenosis after stenting signiﬁcantly contributed to achieving a
“0mmHg”pressure gradient,while inorder to achieve a “0mmHg”pressure gradient, the residual percent
diameter stenosis should be less than around 15%.
© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.ntroduction
The Fontan operation has contributed to improved survival of
atients with univentricular physiology (UVP); concurrently, after
ts ﬁrst description in 1989 [1,2], the use of metallic stents for
ulmonary arterial stenosis (PS) in congenital heart disease has
ecome an important option for treating PS even in patients with
∗ Corresponding author at: Cardiovascular Center, Showa University Northern
okohamaHospital, 35-1Chigasakichuo, Tuzuki-ku, YokohamaCity, Kanagawa224-
503, Japan. Tel.: +81 45 949 7000; fax: +81 45 949 7117.
E-mail address: takanari@nn.iij4u.or.jp (T. Fujii).
ttp://dx.doi.org/10.1016/j.jjcc.2014.02.010
914-5087/© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reUVP. PS in such patients may be attributed to anatomical and
surgical risk associated with growth failure of a segment of the
native vessel, external compression by anatomic structures, and
an inadequate patching at a previous operation. Consequently,
catheter intervention is a reasonable approach to relieve steno-
sis affecting such low pressure systems. The increasing number
of Fontan patients under follow-up means an increased number
of potential cardiac catheterization and interventional procedure
candidates. These procedures may be an important component
of staged surgical palliation for univentricular heart, especially in
the management of PS requiring prompt intervention. Interven-
tionmay allow high-risk surgical repair to be deferred ormay even
replace it.However, littlehasbeenwrittenabout stent implantation
served.
ardiology 64 (2014) 324–327 325
i
s
c
i
c
w
e
M
S
w
f
1
i
U
t
m
l
s
l
s
a
f
W
(
0
c
h
r
t
u
t
b
i
n
o
e
t
t
v
c
c
J
R
w
Table 1
Patients’ proﬁle (basic diagnosis and type of operation).
No. Age Sex Basic diagnosis Type of operation
1 0.8 Female Ebstein, PA BDG
2 1.0 Male HLHS BDG
3 1.0 Male HLHS BDG
4 1.0 Male SRV BDG
5 2.0 Male HLHS Fontan
6 2.0 Male PA/IVS Fontan
7 4.0 Male HLHS BDG
8 8.0 Female TA BDG
9 8.0 Female DORV, PA Fontan
10 17.0 Female TA BDG
11 20.0 Female AVSD BDG
PA, pulmonary atresia; HLHS, hypoplastic left heart syndrome; SRV, single right
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n patients with univentricular heart, and factors associated with
uccessful stent implantation for PS in these patients, while out-
omes of this situation have not been published. Thus, accurately
dentifying theoptimal stent diameter implanted for PSmaybe cru-
ially important for patients with UVP. The purpose of this study
as to evaluate the acute outcome and factors associated with
fﬁcacy of stenting for PS complicating UVP.
ethods
A subanalysis was performed from the data of the Japanese
ociety of Pediatric Interventional Cardiology (JPIC) stent survey,
hich is a retrospective questionnaire-based survey of stenting
or congenital heart diseases from May 1995 to February 2009 at
4 leading hospitals in Japan [3]. We retrospectively analyzed the
mpact of stent implantation for treatment of PS in patients with
VP undertaken to optimize the circulation, with special attention
o morphologic and hemodynamic effectiveness, and factors that
ay have contributed to its effectiveness. We analyzed morpho-
ogic and hemodynamic data of patientswith UVP, who underwent
tenting for PS associated with a mean pressure gradient of at
east 1mmHg. Patients who hadmorphologic stenosis but nomea-
urable pressure gradient across the stenosis were excluded. For
nalysis, 11 patients who received at least one stent implantation
or PS after a bidirectionalGlennor Fontanoperationwere enrolled.
e deﬁned “a 50% increase in the minimum lumen diameter
MLD)” as “morphologically effective” [4], and “an achievement of
mmHg pressure gradient” as “hemodynamically effective.” Each
riterionwasexamined. Furthermore,weanalyzed factors thatmay
ave contributed to hemodynamic effectiveness, including MLD,
eference vessel diameter (RVD), mean pressure gradient through
he target lesion before and after stenting, and balloon diameter
sed for deployment. Percent increase in MLD and percent diame-
er stenosis (%DS) were deﬁned as [(MLD after−MLD before)/MLD
efore] and [(RVD−MLD)/RVD], respectively. If theMLD after stent
s larger than RVD, %DS becomes a negative value; we treated the
egative value as “0%” for the analysis, because the negative value
f %DS does not have a practical meaning. Each data point was
xpressed as a mean value± SD. The values between the “effec-
ive” and “non-effective” groupswere also compared. The Student’s
-test was used to compare means between each group. The cutoff
alue was evaluated using receiver operating characteristic (ROC)
urve of factors which contributed to effective stenting. Statisti-
al analyses were performed with the statistical software package
MP® 10 (SAS Institute Inc., Cary, NC, USA).esults
From May 1995 to February 2009, 31 patients with UVP under-
ent stent implantation. In 11 of them (3 after Fontan operation
able 2
orphologic and hemodynamic parameters, before and after stenting.
No. Type of stent Before stent A
MLD %DS Mean PG M
1 P1506 2.1 73.8 4.0
2 P2006 2.2 60.0 1.0
3 P2007 3.8 32.1 1.0
4 PG2980 3.9 58.1 1.0
5 P2007 3.8 34.5 3.0
6 P2007 4.1 43.8 2.0
7 P3008 4.0 40.3 4.0
8 P3008 2.0 79.2 3.0 1
9 P4010 5.3 33.8 2.0
10 P3008 4.4 47.6 9.0
11 P3008 4.7 63.8 2.0
LD, minimum lumen diameter; %DS, percent diameter stenosis; PG, pressure gradient;ventricle; PA/IVS, pulmonary atresia with intact atrial septum; TA, tricuspid atre-
sia; DORV, double outlet right ventricle; AVSD, atrioventricular septal defect; BDG,
bidirectional Glenn.
and 8 after bidirectional Glenn operation), a stent was implanted
to treat PS with a measurable pressure gradient. The patient pro-
ﬁles are summarized in Table 1. The median age of the patients at
catheterization was 2.0 (0.8–20.0) years. The original Palmaz stent
was used in 10 patients (extra-large, 1; large, 4; medium, 5) and
a Palmaz Genesis stent in one patient. Stents were deployed using
standard techniques. Morphologic and hemodynamic parameters,
before and after stenting, are presented in Table 2. As mentioned
above, we treated the negative value of %DS as “0%”. Stent implan-
tation resulted in a signiﬁcant reduction of the pressure gradient
and %DS in the majority of our patients. Stenting was morpho-
logically effective in all patients, while it was hemodynamically
effective in 6/11 (55%) patients. The comparisons of parameters in
the two groups (hemodynamically “effective” and “non-effective”)
are summarized in Table 3. The %DS after stentingwas signiﬁcantly
lower in the “hemodynamically effective” group than in the “non-
effective” group (2.5±5.5% vs 19.6±13.1%, p=0.017) (Fig. 1). The
cutoff value of %DS after stenting to “hemodynamically effective”
was 14.6%; the sensitivity was 80% and the speciﬁcity was 100%
(area under the curve 0.825, p=0.021) (Fig. 2).
Discussion
PS complicating UVPmay lead to various morbidities, including
changes in the pulmonary vascular bed, increased central venous
pressure, ascites, pleural effusion, and protein losing enteropa-
thy. The long-term outcome after bidirectional Glenn and Fontan
procedures depends on pulmonary artery growth [5]. In these
patients, the pulmonary circulation lacks a pumping chamber and
pulmonarybloodﬂowisdrivenby systemicvenouspressure.Unob-
structed pulmonary blood ﬂow in a univentricular circulation is a
majordeterminantof agood long-termoutcome, and in relievingPS
fter stent RVD % change in MLD
LD %DS Mean PG
5.3 33.8 3.0 8.0 152.4
5.4 1.8 0.0 5.5 145.5
6.3 0 0.0 5.6 65.8
7.4 20.4 1.0 9.3 89.7
6.6 0 0.0 5.8 73.7
6.3 13.7 0.0 7.3 53.7
7.3 0 1.0 6.7 82.5
0.0 0 0.0 9.6 400.0
8.2 0 0.0 8.0 54.7
7.1 15.5 6.0 8.4 61.4
9.3 28.5 1.0 13.0 97.9
RVD, reference vessel diameter.
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Table 3
Comparisons of morphologic and hemodynamic parameters in the two groups.
Parameter “Effective” group “Non-effective” group p value
N=6 N=5
Before stent
MLD 3.5 ± 1.2 3.8 ± 1.0 NS
%DS 47.2 ± 18.8 54.7 ± 10.4 NS
Mean PG 2.0 ± 0.9 4.0 ± 3.1 NS
After stent
MLD 7.1 ± 1.7 7.2 ± 1.4 NS
%DS 2.6 ± 5.5 19.6 ± 13.1 0.017
RVD 7.0 ± 1.6 8.6 ± 3.0 NS
% change in MLD 132.2 ± 135.6 96.8 ± 33.9 NS
MLD, minimum lumen diameter; %DS, percent diameter stenosis; PG, pressure gra-
dient; RVD, reference vessel diameter.
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“ig. 1. The percent diameter stenosis of two groups (hemodynamically “effective”
nd “non-effective”).
n these patients it is important to optimize the long-term hemo-
ynamics. Even mild stenosis might result in further suboptimal
ulmonary artery growth and deterioration of systemic venous
emodynamics [5], and these lesions may become clinically sig-
iﬁcant even in the absence of a measurable pressure gradient in
his low-pressure system [6].Many aspects of liver functionmay be
mpaired by the chronic systemic venous hypertension. However,
here are few reports of stent therapy for PS of UVP [7–14].Kretschmar et al. [14] described their experience with stent
mplantation for PS in children with UVP before and after comple-
ion of partial and total cavopulmonary connections (TCPC). They
mplanted 17 stents for PS in 12 patients before and after TCPC.
ig. 2. Receiver operating characteristics curve of percent diameter stenosis to
0mmHg” pressure gradient.logy 64 (2014) 324–327
PS was treated effectively and safely, while the pressure gradient
was not completely abolished but decreased from 7.1±6.1mmHg
(0–20mmHg) to 1.2±2.2mmHg. They did not calculate the opti-
mal stent size for complete reduction of the pressure gradient.
Moszura et al. [9] also reported their results of stenting for post-
operative PS as a part of multistage treatment for hypoplastic left
heart syndrome. Stenting for PS was performed in 16 patients (28%
of the patients) after bidirectional Glenn and made up the pre-
dominant intervention in their cohort. Pulmonary artery pressure
was reduced and the diameter of the stented vessel was increased
(from a mean of 15.56±6.85mmHg to a mean of 13±5.35mmHg,
and from a mean of 4.56±1.17mm to a mean of 9±1.73mm).
They described how stent implantation into narrowed pulmonary
arteries allowed for improving suitability for the Fontan opera-
tion; however, clear standards for indications and effectiveness for
stent implantation in terms of %DS and pressure gradient were not
shown. Ovroutski et al. [10] reported 20 interventions for reduc-
tion of stenosis in the Fontan pathway in 14 patients. Six of them
were stent implantations for PS. They showed that relief of stenosis
can effectively improve the hemodynamics in the Fontan circu-
lation, even in patients without a measurable pressure gradient.
They speculated that morphologic narrowing without a signiﬁ-
cant pressure gradient may be difﬁcult to ascertain precisely in
the low-pressure system, and might also hinder passive venous
ﬂow, especially in the direction opposite to gravity. They rec-
ommended a percutaneous approach even in cases where the
obstruction is angiographically mild with no signiﬁcant pressure
gradient.
Stenting in the Fontan route was also applied to the extra car-
diac (EC) conduit or lateral tunnel (LT) pathway [6,13,15,16]. Ewert
et al. [13] reported the retrospective analysis of 60 implanted CP
stents including six cases of TCPC. A residual pressure gradient
of 4mmHg after attempted balloon dilatation and morphological
stenosiswithout pressure gradientwere the criteria for stent place-
ment. Six stents were placed in caval veins and EC conduits and
pressure gradients dropped from 4mmHg (range 4–20mmHg) to
0mmHg (range 0–3mmHg). Although, not intended for the pul-
monary artery, this study is similar to our study from the point
of view of targeting the low-pressure system in a Fontan type cir-
culation. Mets et al. [6] also described their experience with stent
implantation for obstruction of intracardiac LT Fontan pathways.
Fifty-one patients underwent stent implantation for LT pathway
stenosis. These patients had signiﬁcantly higher inferior vena cava
pressures than controls, but only 35% had a measurable pressure
gradient in the catheterization laboratory. Stenting increased the
meandiameter of the LT stenosiswith fewadverse events andelim-
inated the pressure gradient when present. However, we may not
always be able to achieve enough % diameter decrease in stenosis
in PS, because of its complex anatomy in contrast to the relatively
straight EC conduit or LT stenosis.
The magnitude of resistance in the venous system of Fontan
patients tends to be underestimated during catheterization,
because catheterization is performed under resting conditions or
under sedation or general anesthesia [6]. Therefore, a measurable
pressure gradient across the stenosis is signiﬁcant from the point
of view of energy loss, and achievement of “0mmHg” pressure gra-
dient of the pulmonary stenosis derived from stent implantation is
beneﬁcial [6]. Although the optimal size of stent for PS in UVP is
unknown, we consider it is likely to be large if required to achieve
“0mmHg” pressure gradient. According to our study, “0mmHg”
pressure gradient of the pulmonary stenosis is likely to be achieved
in patients with UVP if residual %DS is less than around 15%, and
this seems to be a reasonable target. Our data are incomplete and
we are unable to determine clinical beneﬁt, so the clinical implica-
tions of stenting for PS of UVP and target size for stenting deserve
further investigation.
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imitations
This study is based on data from a questionnaire survey, and
s limited to the background data of the patients, morphologi-
al measurement of the target, and pressure gradients. Lack of
ther hemodynamic data such as central venous pressure and
rterial oxygen saturation limits the analysis. Consequently, this
tudy has strong selection bias because of excluding patients with
“0mmHg” pressure gradient even if they had morphological
arrowing. Furthermore, there are no data on deﬁnitive clinical
eneﬁts related to stenting for PS in patients with UVP. The small
umber of patientsmay limit the signiﬁcance of statistical analysis.
owever, as assessment of the beneﬁts of stenting for PS in the low-
ressure cavopulmonary system is still unclear, we believe it will
e beneﬁcial to achieve “0mmHg” pressure gradient at rest during
atheterization.
onclusion
Although stenting was morphologically effective in all patients,
0mmHg” pressure gradient was achieved only in 55%. The %DS
fter stenting signiﬁcantly contributed to achieving “0mmHg”
ressure gradient, while in order to achieve “0mmHg” pressure
radient, residual %DS should be less than around 15% in patients
ith univentricular physiology complicated by pulmonary steno-
is.
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